BA
VIRX

Boston Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Boston Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-105
Closed -$114K – 593
2013
Q2 		$114K Buy
+105
New +$117K 0.01% 551

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Advisors's VIRX Position: Q3 2013 in Review

Boston Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2013, closing a stake of 105 shares — an estimated $114K sold.

Boston Advisors first reported a position in VIRX in Q2 2013 and held it in 1 quarter. The position peaked at $114K in Q2 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q3 2013.

  • Boston Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Boston Advisors sold 105 Viracta Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $114K.
  • Boston Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Boston Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $114K in Q2 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2013.

Based on Boston Advisors's 13F filing for Q3 2013, filed 23 Oct 2013.